Search Result

Results for "

free+fatty+acid+receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylin Receptor (1) Amyloid-β (1) Antibiotic (1) Bacterial (1) CaMK (1) CD38 (1) CGRP Receptor (2) Chemerin Receptor (1) Drug Derivative (3) Endogenous Metabolite (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) Ferroportin (1) Fluorescent Dye (1) Free Fatty Acid Receptor (24) Fungal (1) GCGR (13) GLP Receptor (16) GLUT (1) GnRH Receptor (1) GPR84 (2) HDAC (1) Histone Methyltransferase (1) Insulin Receptor (1) Isotope-Labeled Compounds (5) MARCKS (2) Melanocortin Receptor (1) mTOR (1) nAChR (1) Natriuretic Peptide Receptor (NPR) (1) Neuropeptide Y Receptor (1) Opioid Receptor (1) p38 MAPK (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phospholipase (1) PKC (2) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Renin (1) RXFP Receptor (1) TNF Receptor (1) Vasopressin Receptor (3)
By Research Areas:	Cancer (11) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (15) Metabolic Disease (42) Neurological Disease (9)

By Targets:

Amylin Receptor (1)

Amyloid-β (1)

Antibiotic (1)

Bacterial (1)

CaMK (1)

CD38 (1)

CGRP Receptor (2)

Chemerin Receptor (1)

Drug Derivative (3)

Endogenous Metabolite (1)

Ephrin Receptor (1)

Epigenetic Reader Domain (1)

Ferroportin (1)

Fluorescent Dye (1)

Free Fatty Acid Receptor (24)

Fungal (1)

GCGR (13)

GLP Receptor (16)

GLUT (1)

GnRH Receptor (1)

GPR84 (2)

HDAC (1)

Histone Methyltransferase (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (5)

MARCKS (2)

Melanocortin Receptor (1)

mTOR (1)

nAChR (1)

Natriuretic Peptide Receptor (NPR) (1)

Neuropeptide Y Receptor (1)

Opioid Receptor (1)

p38 MAPK (1)

PD-1/PD-L1 (2)

Peptide-Drug Conjugates (PDCs) (1)

Phosphatase (1)

Phospholipase (1)

PKC (2)

PPAR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Renin (1)

RXFP Receptor (1)

TNF Receptor (1)

Vasopressin Receptor (3)

By Research Areas:

Cancer (11)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (42)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective *amylin receptors* (AMYR) and calcitonin G protein-coupled receptor (CTR)** agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-12940

GLPG0974 15+ Cited Publications	Free Fatty Acid Receptor	Metabolic Disease
GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-P1125

4-CMTB 5+ Cited Publications	Free Fatty Acid Receptor	Others
4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC₅₀=6.38) .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-116522

AR420626 4 Publications Verification	Free Fatty Acid Receptor Histone Methyltransferase HDAC mTOR CaMK p38 MAPK Epigenetic Reader Domain GLUT nAChR TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC₅₀=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca ²⁺ signal-mediated glucose uptake and improve diabetes .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-124571

ZQ-16	GPR84	Inflammation/Immunology
ZQ-16 is a potent and selective GPR84 agonist with an EC₅₀ value of 0.213 μM. ZQ-16 has no activity on the other free fatty acid receptors (FFARs), including GPR40, GPR41, GPR119 and GPR120 .

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-W009081

Tricosanoic acid	Free Fatty Acid Receptor	Neurological Disease
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting *glucagon-like peptide-1 receptor* 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-116263

CATPB 2 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
CATPB is a potent, selective free fatty acid receptor 2 (FFA2R/GPR43) antagonist .

HY-148418

TUG-499	Free Fatty Acid Receptor	Metabolic Disease
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC₅₀ of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .

HY-103083

GPR40 agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 4 is a potent free fatty acid receptor 1 (FFA1/ GPR40) agonist with a pEC₅₀ of 7.54.

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-153476A

*GIP/GLP-1 dual receptor* agonist-1 sodium**	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

*GIP/GLP-1 dual receptor* agonist-1**	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-147351

GPR40 agonist 6	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 (FFAR1 or GPR40) agonist with an EC₅₀ of 0.058 μM .

HY-111763

GPR40/FFAR1 modulator 1	Free Fatty Acid Receptor	Metabolic Disease
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for *Gq-coupled free fatty acid receptor* 1 (GPR40/FFAR1)** .

HY-12940A

(S)-GLPG0974	Free Fatty Acid Receptor	Metabolic Disease
(S)-GLPG0974 is the isomer of GLPG0974 (HY-12940), and can be used as an experimental control. GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-N3977

Grifolic acid	Free Fatty Acid Receptor	Inflammation/Immunology
Grifolic acid is a phenolic compound that is first extracted from the mushroom Albatrellus confluens. Grifolic acid acts as an agonist of the free fatty acid receptor (FFAR4/GPR120) .

HY-59384

MOMBA	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
MOMBA is a selective FFA2 (Free Fatty Acid Receptor 2) orthosteric agonist that activates receptor signaling pathways by binding to the orthosteric site of FFA2 with high specificity. MOMBA holds potential for research on metabolic and inflammatory diseases .

HY-162689

GprA	Free Fatty Acid Receptor	Inflammation/Immunology
GprA is a new synthetic agonist of G-protein-coupled receptor 120/free fatty acid receptor 4 (GPR120/FFAR4), with an AC₅₀ of 203 nM on human GPR120 full isoform. GprA can be used in the research for NAFLD .

HY-130120

HWL-088	Free Fatty Acid Receptor PPAR	Metabolic Disease
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC₅₀ of 18.9 nM) with moderate PPARδ activity (EC₅₀ of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .

HY-173556

GPR84 agonist-2	GPR84	Inflammation/Immunology
GPR84 agonist-2 is a selective GPR84 agonist with no activity at free fatty acid receptors. GPR84 agonist-2 enhances GPR84-mediated signaling above basal levels and potentiates agonist-induced GPR84 activation. GPR84 agonist‑2 can be used for research on GPR84-related physiological mechanisms .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .

HY-136896

FFA3 agonist 1	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
FFA3 agonist 1 is an agonist of free fatty acid receptor 3 (FFA3). FFA3 agonist 1 regulates the health effect of intestinal microbiota by activating FFA3 .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

Cat. No.	Product Name	Target	Research Area

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective *amylin receptors* (AMYR) and calcitonin G protein-coupled receptor (CTR)** agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting *glucagon-like peptide-1 receptor* 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-153476A

*GIP/GLP-1 dual receptor* agonist-1 sodium**	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

*GIP/GLP-1 dual receptor* agonist-1**	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10378

GPR10 agonist 1	GnRH Receptor	Metabolic Disease
GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC₅₀ values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity .

HY-P10910

Vensemaglutide	GLP Receptor	Metabolic Disease
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-109166

Amdakefalin	Opioid Receptor	Neurological Disease
Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P10381

palm11-TTDS-PrRP31	Peptides	Others
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC₅₀: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .

HY-P2595

SKF 103784	Endogenous Metabolite	Cardiovascular Disease
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P11759

Myr-transportan-Cys	Drug Derivative	Cancer
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .

HY-N17580

Lyciumin D	Renin	Cardiovascular Disease
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Anthocyans Flavonoids Classification of Application Fields Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields Source Classification	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-W009081

Tricosanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Free Fatty Acid Receptor
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-N3977

Grifolic acid	Microorganisms Classification of Application Fields Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification	Free Fatty Acid Receptor
Grifolic acid is a phenolic compound that is first extracted from the mushroom Albatrellus confluens. Grifolic acid acts as an agonist of the free fatty acid receptor (FFAR4/GPR120) .

HY-N17580

Lyciumin D	Structural Classification Lycium barbarum L. Cyclopeptides Phenols Solanaceae Plants Source Classification	Renin
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

Cat. No.	Product Name	Chemical Structure

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-178395S

Tricosanoic acid-d45

Tricosanoic acid-d₄₅ is the deuterium labeled Tricosanoic acid (HY-W009081). Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-W746542

Tricosanoic acid-d3

Tricosanoic acid-d₃ is the deuterium labeled Tricosanoic acid (HY-W009081). Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81225

	GPR43 Antibody GPCR GPR43; FFA2R; Ffar2; FFAR2_HUMAN; free fatty acid activated receptor 2; Free fatty acid receptor 2; G protein coupled receptor 43; G protein-coupled receptor 43; G-protein coupled receptor 43; GPR 43; GPCR 43.	IHC-P, IHC-F, ICC/IF, ELISA, IF-Tissue	Human, Mouse
	GPR43 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GPR43.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

free+fatty+acid+receptor

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products